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Adaptive responseTherapies targeting oncogenic drivers rapidly induce compensatory adaptive responses that blunt drug effectiveness,
contributing to therapeutic resistance. Adaptive responses are characteristic of robust cell signaling networks, and thus
there is increasing interest in drug combinations that co-target the driver and the adaptive response. An alternative
approach to co-inhibiting oncogenic and adaptive targets is to identify a critical node where the activities of these
targets converge. Nodes of convergence between signaling modules represent potential therapeutic vulnerabilities
because their inhibition could result in the collapse of the network, leading to enhanced cytotoxicity. In this report
we demonstrate that p70S6 kinase (p70S6K) can function as a critical node linking HER-family and
phosphoinositide-3-kinase (PI3K)pathway signaling.Weusedhigh-throughput combinatorial drug screening to iden-
tify adaptive survival responses to targeted therapies, and found that HER-family and PI3K represented compensatory
signaling pathways. Co-targeting these pathways with drug combinations caused synergistic cytotoxicity in cases
where inhibition of neither target was effective as a monotherapy. We utilized Reverse Phase Protein Arrays and
determined that phosphorylation of ribosomal protein S6 was synergistically down-regulated upon HER-family and
PI3K/mammalian target of rapamycin (mTOR) co-inhibition. Expression of constitutively active p70S6K protected
against apoptosis induced by combined HER-family and PI3K/mTOR inhibition. Direct inhibition of p70S6K with
small molecule inhibitors phenocopied HER-family and PI3K/mTOR co-inhibition. These data implicate p70S6K as a
critical node in the HER-family/PI3K signaling network. The ability of direct inhibitors of p70S6K to phenocopy co-
inhibition of two upstream signaling targets indicates that identiﬁcation and targeting of critical nodes can overcome
adaptive resistance to targeted therapies.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).ositide-3-kinase; RPPA, Reverse
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Resistance to targeted therapies often occurs because compensatory
signaling blunts the short-term cytotoxic effects of target inhibition,
without selection for resistant mutant cells. This mechanism of
resistance can be intrinsic or adaptive, but in either case there is a
perceived need to develop combinations of drugs that target not only
the oncogenic driver, but also the compensatory response.We previously
reported that inhibition of the MAP kinase (MAPK) pathway in prostate
cancer xenografts induced upregulation not only of many components
of the MAPK pathway, but also of other signaling pathways (e.g. Wnt,
STAT); co-inhibition of these adaptive responses caused synergistic
cytotoxicity [1]. Numerous subsequent reports support this concept. For
example, in colorectal cancer cells, co-activation of MET and epidermal
growth factor receptor (EGFR) resulted in synergistic proliferation due
to the ability of both proteins to cause increased signaling through the
MAPK and AKT pathways [2]. In non-small cell lung cancer (NSCLC),the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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neous co-targeting of these receptors resulted in enhanced apoptosis
compared to inhibition of only one target [3]. Compensatory signaling
can also be induced by relief of negative feedback. For example, inhibition
of MAPK signaling leads to upregulation of phosphoinoside-3-kinase
(PI3K) and AKT signaling, and vice versa [4–6], thus leading to an interest
in drug combinations that target both of these pathways. Another exam-
ple is the upregulation of receptor tyrosine kinase (RTK) signaling in re-
sponse to inhibition of PI3K [7], AKT [8] or BRAF [9]. AKT-mediated
phosphorylation negatively regulates the forkhead box (FOX) protein
family of transcription factors [10], leading to upregulation of a number
of RTKs through a FOXO-dependentmechanism, thereby blunting the ef-
fects of drugs targeting PI3K or AKT. Similarly, BRAF inhibition leads to
the dysregulation of FOXD3 activity, which in turn reduces the apoptosis
generated through inhibition of mutant-BRAF driven melanomas by
vemurafenib [11]. Co-inhibition of HER-family proteins along with AKT
or BRAF resulted in enhanced anti-tumor beneﬁt compared to either
therapy individually1 [8].
Adaptive responses to single-agent targeted therapy are extraordi-
narily complex [1,12] and differ substantially between cancer cell lines
even within a single tumor and driver type1. Therefore, it is difﬁcult to
determine the optimal drug combination based on genotypic or molec-
ular proﬁling of cells or tumors treated with a targeted agent. We and
others have taken an empirical approach to identifying the adaptive
responses that are most signiﬁcant for maintaining the growth and
survival of cells subjected to single-target inhibition, by screening com-
binations of targeted inhibitors for synergistic cytotoxicity2 [13–16].
Among the combinations we identiﬁed that have near-term potential
clinical utilitywas co-inhibition ofHER-family RTKs andPI3K/mammalian
target of rapamycin (mTOR), which were synergistically cytotoxic where
single-agent inhibition was ineffective. The potential utility of using drug
combinations that inhibit these two target categories iswidely recognized
[4,7,17], which supports the validity of our approach.
Despite their potential beneﬁts, there are numerous challenges
associated with developing drug combinations. Synergistic cytotoxicity
against tumors may be associated with enhanced toxicity for patients
and an erosion of therapeutic beneﬁt. This problem is exacerbated by
the fact that each drug will have its own palette of off-target effects,
and the combination may have adverse interactions. In addition, there
are challenges associated with developing such combinations associated
with issues of pharmacokinetics, drug interactions and intellectual
property. Thus there is increasing interest in identifying points of
convergence between signaling pathways that would yield targets
whose inhibition would block two pathways that otherwise would be
compensatory.
Signaling pathways are linked together in inter-dependent networks,
communicating by feedback and feed-forward regulatory loops. These
signaling networks have emergent properties associated with robust
systems [18,19], raising the possibility that they contain critical nodes
within the system, whose inhibition would lead to system collapse.
Targeting such a critical node could enable the use of a single drug that
might not only phenocopy the biological effects of dual-target inhibition,
but also be effective in a broader range of biological settings.
In the current communicationwe identify p70S6 kinase (p70S6K) as
being a critical node that links HER-family and PI3K pathway signaling,
and is an effective target for single-agent therapy. We found that HER-
family and PI3K/mTOR co-inhibition caused synergistic cytotoxicity,
and utilized Reverse Phase Protein Arrays (RPPA) to identify p70S6K
as being synergistically inhibited in response to these drug combinations.
Expression of a constitutively active p70S6K construct protected the cells
against apoptosis induced by combined HER-family and PI3K/mTOR
inhibition. Direct inhibition of p70S6K using small molecule inhibitors
phenocopied the growth inhibition and apoptosis caused by HER-1 D.G. Roller et al. Manuscript in preparation.
2 M.J. Axelrod et al. Manuscript submitted.family and PI3K/mTOR co-inhibition. Thus, p70S6K functions as a critical
node in the signaling network that links HER-family and PI3K pathway
signaling, and is an under-explored target for development of small
molecule inhibitors that could function as single agents.
2. Methods and materials
2.1. Cell line and reagents
UMUC-6 bladder cancer cells were a gift from Dr. Dan Theodorescu
(University of Colorado). Cal27 HNSCC cells were obtained from the
American Type Culture Collection (ATCC). SCC61 HNSCC cells were a
gift from Dr. Wendell Yarbrough (Vanderbilt University). UMUC-6
cells were maintained in MEM (Invitrogen) supplemented with 5%
FBS (Gemini, Bio-products), 1 mM sodium pyruvate (Invitrogen) and
0.1 mM MEM non-essential amino acids (Invitrogen). Cal27 and
SCC61 cells weremaintained in DMEM/F-12media (Invitrogen) supple-
mented with 5% FBS and 400 ng/mL hydrocortisone (Sigma-Aldrich).
Cells were grown in a humidiﬁed 37 °C incubator with 5% CO2. All cell
lineswere routinely tested and found to be free ofmycoplasma contam-
ination using MycoAlert (Lonza). Cell line identities were veriﬁed by
STR analysis and comparison to published databases (University of
Arizona). LY294002 was purchased from Calbiochem, Lapatinib from
L.C. Laboratories, NVP-BEZ235 and BMS599626 from ChemieTek,
PF04691502 and AT7867 from Selleckchem, and Ro31-8220 from
Enzo Life Sciences. All of the primary antibodies used for Western
blotting in this study were purchased from Cell Signaling Technologies
with the exception of the total and phosphorylated ERK antibodies
(Sigma) and the tubulin antibody (EMD Biosciences). The ﬂuorescently
labeled secondary antibodies used forWestern blottingwere purchased
from Licor. The antibodies used for ﬂow cytometry were as follows: the
anti-rat HA-tag antibody was purchased from Roche, the anti-rat FITC-
conjugated secondary antibody from Invitrogen, the anti-rabbit PE-
conjugated secondary antibody from Santa Cruz, and the cleaved
Caspase 3 and phopho-S6 primary antibodies from Cell Signaling. 4′,6-
Diamidino-2-phenylindole (DAPI) was from Sigma-Aldrich.
2.2. Generation of stable UMUC-6-E389 cells
The plasmid containing the HA-p70S6K-E389-ΔCT construct was
from Addgene (plasmid # 8993) [20] transferred into the pSLIK vector
using Gateway recombination cloning according to the manufacturer's
protocol (Invitrogen) as previously described3. The pSLIK-HA-p70S6K-
E389-ΔCT vector was transfected into 293-T cells along with the
lentiviral packaging and envelope vectors psPAX2 and pMDG by
calcium phosphate transfection. Lentivirus was collected two days
after transfection and ﬁlter sterilized through a 0.24 μm ﬁlter. UMUC-6
cells were transduced with lentivirus containing the pSLIK-E389
DNA or mock transduced. Both sets of cells were then exposed to
100 μg/mL G418 until the mock-transduced plate was completely
cleared. HA expression in the UMUC-6-E389 cells upon 2 μg/mL
doxycycline treatment was assessed by ﬂow cytometry.
2.3. Flow cytometry
Cells were plated for 24 h in phenol-red free RPMI-1640 and then
treated as described in the text. Both ﬂoating and adherent cells were
collected and pooled. The cells were ﬁxed with paraformaldehyde and
permeabilized with ice-cold methanol and stored in methanol at
−20 °C until use. Prior to staining, the cells were pelleted in siliconized
tubes and washed twice with PBS containing 1% BSA. The cells were
then blocked using PBS containing 2% donkey serum, 1% BSA, 0.1%
Triton X-100, and 0.05% Tween 20 for 10 min. Cells were then stained3 C.C. Wang et al. Manuscript under review.
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PBS with 1% BSA for 1 h. From this point forward, the cells were kept
in the dark in order to preserve the ﬂuorescence signal. Cells were
then stained with the appropriate secondary antibody for 30min. Final-
ly, cells were stained with 1 μg/mL DAPI in PBS. The cells were stored at
4 °C overnight and then assayed using a FACSCalibur ﬂow cytometer.
Single stained controls were also assayed on the FACSCalibur to serve
as compensation controls. Data analysis, including compensation, was
performed using Flo-Jo ﬂow cytometry analysis software.
2.4. Reverse phase protein array
RPPA analysis was performed by the RPPA Core Facility at MD
Anderson. Cell lysates were prepared in accordance with their recom-
mended protocols. Brieﬂy, cells were treated with either DMSO,
0.5 μM lapatinib, 5 μM LY294002, or the combination for 24 h. Cell ly-
sates were prepared in the same manner as for Western blotting (see
below) with the exception that the lysis buffer used was a 1:1 mixture
of 2x sample buffer and Tissue Protein Extraction Reagent (T-PER)
(Pierce). Lysates were then processed according to the MD Anderson
RPPA Core protocol.
2.5. Growth assays
Cells were plated in phenol-red free RPMI1640+ 0.5% FBS at a den-
sity of 3 × 103 cells/well in a volume of 80 μL for 24 h in 96-well plate
format. The inhibitors and solvent were at a concentration 10× greater
than the ﬁnal experimental concentration. 10 μL of each drug and/or
solvent was added to the appropriate wells. Cells were then incubated
for 72 h; after which 10 μL of alamarBluewas added, cells were incubated
for 4 h, and assayed using a ﬂuorescence plate reader with a 540/25 nm
excitation ﬁlter and a 620/40 nm emission ﬁlter.
2.6. Cell lysis and Western blotting
Cells were plated for 24 h in phenol-red free RPMI 1640 + 0.5%
FBS and then treated as described in the text. Prior to cell lysis, each
plate was treated with 1 μM pervanadate and 5 nM Calyculin-A for
1 min. The medium was aspirated off and the cells were washed for 30 s
with ice-cold PBS containing pervanadate and Calyculin A. The PBSwas re-
moved and cells were lysed in a Triton-based lysis buffer (1% Triton X-100,
50mMTris pH7.5, 100mMNaCl, 50mMNaF, and5mMEDTA) containing
1 μg/mL pepstatin, 1 μg/mL leupeptin, 1 mM phenylmethylsulfonyl
ﬂuoride, 200 μM orthovanadate, 50 mM ß-glycerophosphate, and 0.4 μM
microcystin. Western blotting was carried out as previously described
[21]. Immunoblots were analyzed using the Odyssey (LICOR Biosciences)
imaging system.
2.7. Statistics and synergy
The primary method of analysis is 2-way ANOVA for randomized
block designs, which were used to control for experiment-to-
experiment variation [22]. Contrasts were used to make speciﬁc compari-
sons between groups, and where appropriate, data were transformed to
the log scale to facilitate interpretations as fold changes. Synergy was
assessedby comparingobservedvalues andvalues thatwouldbepredicted
by Bliss-independence [23,24] and by testing for interactions terms in the
two-way ANOVA.
3. Results
3.1. Concurrent inhibition of HER-family and PI3K/mTOR signaling results
in synergistic cytotoxicity mediated by apoptosis
We tested over 500 drug combinations for synergistic cytotoxic
effects in 21 epithelial cancer cell lines representing three distinctcancer lineages2 [14]. One combination that we identiﬁed as synergistic
using the Blissmodel of additivity is the combination of aHER-family ki-
nase inhibitor and a dual PI3K/mTOR inhibitor. This combination caused
synergistic cytotoxicity inmultiple cell lines and cancer lineages such as
bladder (UMUC-6) and head and neck squamous cell carcinoma
(HNSCC) (Cal27 and SCC61) (Fig. 1 A–C). To be certain that the biolog-
ical effects of these drugs were due to inhibition of the expected target
enzyme and not a consequence of off-target effects, we determined
that multiple pharmacophores with the same putative target elicited
the same biological effects, as described previously [14]. BMS599626,
lapatinib, and AG1478 were functionally equivalent (Fig. 1 and data not
shown), thus validating the HER family as the functional target. Similarly,
NVP-BEZ235 (BEZ235), PF04691502 and LY294002 could substitute for
each other (Fig. 1 and data not shown), thus validating PI3K and mTOR
as the functionally signiﬁcant targets in these combination experiments.
AlamarBlue was used to assay for growth inhibition in our high-
throughput screens, but since this agent monitors cell metabolism
rather than cell death, we directly tested the effects of these drug com-
binations on apoptosis (Fig. 1 D–E). In all three cell lines, combination
treatment resulted in a 2–4 fold increase in apoptosis compared to vehi-
cle treated cells and demonstrated enhancement of the apoptotic effect
compared to cells treated with either a HER-family kinase or PI3K/
mTOR inhibitor alone.
3.2. p70S6K is a node of convergence between HER-family and PI3K
pathway signaling
To determine a molecular basis for the synergistic cytotoxicity we
observed upon treatment with HER-family kinase and PI3K/mTOR in-
hibitors, we performed RPPA analysis on UMUC-6 cells treated with
lapatinib (HER-family kinase inhibitor), LY294002 (PI3K/mTOR inhibi-
tor) and the combination. 209 epitopes, including 56 phospho-
epitopes, were examined and the data were calculated as positive or
negative fold changes compared to the vehicle treated control cells.
The phospho-epitopes were then rank-ordered according to the fold-
change decrease in phosphorylation upon combination treatment. The
most robust changes in phosphorylation were observed at multiple
epitopes of the ribosomal protein S6, a substrate of p70S6K (Fig. 2A).
Subsequent Western blots conﬁrmed the results of the RPPA in
UMUC-6 cells (Fig. 2B). In addition, these Western blots demonstrated
that the activating phosphorylations on p70S6K (T389 and T412/S421)
were also inhibited by combination treatment with lapatinib and
LY294002. To determine whether other combinations of HER-family
kinase and PI3K/mTOR inhibitors that caused synergistic cytotoxicity in
other cell lines had similar effects, we treated Cal27 and SCC61 cells
with lapatinib plus PF-04691502 and BMS599626 plus PF-04691502, re-
spectively. In both cases, S6 phosphorylationwas decreased in the combi-
nation treated cells compared to either of the single-drug treated
conditions (Fig. 2C–2E).
3.3. p70S6K activity mediates the cytotoxic response upon treatment with
HER-family and PI3K/mTOR inhibitors
To test the functional role inhibition of p70S6K plays in the cytotox-
icity that occurs from inhibiting the HER family and PI3K pathways, we
performed an epistasis analysis in which cells dually inhibited by
BEZ235 and lapatinib were “rescued” from apoptosis by expression of
a constitutively active p70S6K mutant. We generated stable UMUC-6
cells containing a doxycycline-inducible constitutively active p70S6K
mutant, HA-p70-E389-ΔCT (UMUC-6-E389). UMUC-6-E389 cells were
treated with 2 μg/mL doxycycline or vehicle for 48 h. After that time,
2.5 μM lapatinib, 750 nM BEZ235, the drug combination, or the appro-
priate vehicle control were added for 24 h. UMUC-6 parental cells that
were treated with 2 μg/mL doxycycline or vehicle for 48 h were also
drug treated for 24 h. The cells were then collected and assayed for
levels of phosphorylated S6 and apoptosis by ﬂow cytometry. In the
Fig. 1. Combinatorial drug screening revealed synergy betweenHER-family and PI3K/mTOR inhibitors inmultiple cell lines. The Blissmodel of additivitywas used to predict additive levels
of cytotoxicity in combination treated cells. A. UMUC-6 bladder cancer cells were treated with 250 nM, 500 nM, and 1 μM lapatinib (HER-family inhibitor) in combination with 50 nM,
100 nM, and 250 nM NVP-BEZ235 (PI3K/mTOR inhibitor). B. Cal27 HNSCC cells were treated with 78 nM, 156 nM, and 313 nM lapatinib in combination with 16 nM, 32 nM, and
63 nM PF04691502 (PI3K/mTOR inhibitor). C. SCC61 HNSCC cells were treated with 2.5 μM, 5 μM and 10 μM BMS599626 (HER-family inhibitor) in combination with 16 nM, 32 nM,
and 63 nM PF04691502. All data points represent the average of three independent experiments. The vertical error bars represent the standard error of the mean of the Bliss predicted
additive cytotoxicity calculations. The horizontal error bars represent the standard error of the mean of the experimental cytotoxicity values. D. UMUC-6 (500 nM lapatinib, 100 nM
BEZ235), Cal27 (78 nM lapatinib, 63 nM PF04691502), and SCC61 (2.5 μMBMS599626, 63 nMPF04691502) were treated for 72 h assessed for apoptosis by staining for caspase 3 cleavage.
E. Quantiﬁcation of fold change in apoptosis compared to control cells for three independent experiments in each cell line. Bars represent the mean fold change in apoptosis and error bars
represent the standard error of the mean.
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ly half the vehicle treated cells stained positive for pS6. Treatment with
lapatinib and BEZ235 in the absence of doxycycline reduced the per-
centage of pS6+ cells to 5% and 15% respectively. Treatment with the
combination resulted in less than 1% of the cells staining positive for
pS6. In UMUC-6-E389 cells treated with doxycycline, induction of the
constitutively active p70 E389 construct resulted in an increased level
of S6 phosphorylation in vehicle treated cells that stained positive for
HA. Expression of this construct also provided signiﬁcant protection
against loss of S6 phosphorylation in both single drug treated cells and
in cells treated with both lapatinib and BEZ235 that stained positive
for HA (Fig. 3 A&C). These data indicate that the cells expressing the
p70 E389 construct retain p70S6K activity in the presence of lapatinib
and BEZ235.
Next, we looked at the effects of the p70 E389 construct on survival.
Treatment with 2.5 μM lapatinib increased the percentage of
doxycycline-naïve cells that stained positive for cleaved caspase 3 by2.5-fold. Although 750 nMBEZ235 had no effect on apoptosis as a single
drug, the combination of lapatinib and BEZ resulted in a 3.7-fold in-
crease in apoptosis versus control treated cells. The addition of doxycy-
cline and expression of p70 E389 resulted in signiﬁcant decreases in
apoptosis in all treatment conditions in the population of cells express-
ing theHA-tagged construct. In cells treatedwith the drug combination,
expression of p70 E389 resulted in a 23% reduction of apoptosis, from
27.6% to 4.6%, versus cells that were not treated with doxycycline, a
level of apoptosis even lower than that seen in the untreated controls
(Fig. 3 B&D). UMUC-6 E389 cells that were not treatedwith doxycycline
behaved similarly to parental UMUC-6 cells in both the absence and
presence of doxycycline (Supplemental Figure S1). Taken together,
these data demonstrate that expression of a constitutively active
p70S6K construct can rescue cells from the apoptotic effects of
combined PI3K/mTOR and HER family kinase inhibition suggesting
that p70S6K is a critical node within the PI3K and HER family signaling
network, and its activity is sufﬁcient to maintain cell survival.
AB
C
D
E
Fig. 2. p70S6K is a node of convergence between HER-family and PI3K/mTOR signaling in multiple cellular contexts. A. UMUC-6 cells were treated for 24 h with 500 nM lapatinib, 5 μM
LY294002, or the combination. Phosphorylations were assessed by RPPA. Data is expressed as a fold change versus vehicle treated controls. B. UMUC-6 cells were treated as in A and an-
alyzed byWestern blot for the indicated phosphorylated and total proteins. C–D. Cal27 (C) cells were treated for 24 hwith 78 nM lapatinib, 63 nMPF04691502 or the combination. SCC61
(D) cellswere treated for 24 hwith 2.5 μMBMS599626, 63nMPF04691502, or the combination. Cellswere analyzedbyWesternblot for phosphorylated and total S6, aswell as tubulin as a
loading control. Images are representative of three independent experiments. E. Quantiﬁcation of the data from C and D. Bars represent the mean of three independent experiments and
error bars represent the standard error of the mean.
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family kinase and PI3K/mTOR inhibition
To determine whether p70S6K could function as a single thera-
peutic target with efﬁcacy that emulates the combination therapy,
we utilized a small molecule inhibitor of p70S6K, AT7867. AT7867
has been shown to be an effective inhibitor of cancer cell growth
both in vitro and in vivo [25]. Treatment of all three cell lines with
AT7867 for 72 h caused a dose-dependent decrease in growth with
an average IC50 of approximately 4 μM (Fig. 4A). This decrease
corresponded to a similar dose dependent decrease in the level of
ribosomal protein S6 phosphorylation upon treatment with similar
concentrations of AT7867 (Fig. 4B). These data are consistent with
inhibition of p70S6K activity resulting in growth inhibition. The inhi-
bition of growth and S6 phosphorylation upon treatment with
AT7867 were similar to those observed upon treatment with the
HER family kinase and PI3K/mTOR inhibitor combinations. To determine
whether inhibition of p70S6K activity produced effects on apoptosis
comparable to the combination of HER family kinase and PI3K/mTOR
inhibitors (Fig. 1), we treated cells with increasing concentrations of
AT7867 for 72 h and performed ﬂow cytometry to assess the levels of
apoptosis in these cells. AT7867 caused a dose-dependent increase in
apoptosis in all three cell lines tested (Fig. 4C–D). These results were
similar to the biological effects caused by the combination treatment
(compare Figs. 1 and 4).AT7867 has been demonstrated to inhibit the kinase activity of pro-
teins other than p70S6K at the concentrations that caused cytotoxicity
and apoptosis, such as other AGC kinases including protein kinase A
(PKA) and AKT [25]. Therefore, we tested another structurally distinct
compound, Ro31-8220, that has been shown to inhibit p70S6K activity.
Although Ro31-8220 is primarily used as a protein kinase C (PKC) inhib-
itor, it inhibits p70S6K at a similar potency [26]. Importantly, the pub-
lished range of Ro31-8220 and AT7867 targets is non-overlapping
with the exception of p70S6K (Supplemental Table 1). Treatment with
2.5 μM Ro31-8220 resulted in a 72% increase in cytotoxicity compared
to vehicle control cells in Cal27 cells (Fig. 4E). Treatment with the
same concentration of Ro31-8220 caused a 95% reduction in S6 phos-
phorylation at serine 235/236 and an 84% reduction at serine 240/244,
indicating that Ro31-8220 is a potent inhibitor of p70S6K activity at
this concentration (Fig. 4F). Taken together, the effects of AT7867 and
Ro31-8220 indicate that inhibition of p70S6K results in signiﬁcant cyto-
toxicity and apoptosis that is comparable to the effects of combination
treatment using HER family and PI3K/mTOR inhibitors.
4. Discussion
We have identiﬁed p70S6K as a critical node of convergence
between the HER family and PI3K signaling modules, and shown that
targeting this enzymewith small molecule inhibitors can provide an al-
ternative to drug combinations that target both pathways. Although the
AB
C
D
Fig. 3. Constitutive activation of p70S6K protects cells from combination-induced apoptosis. UMUC-6 cells were transduced by lentivirus containing a construct encoding a doxycycline-
inducible HA-tagged C-terminus truncated copy of p70S6K with a threonine to glutamate mutation at position E389 (UMUC-6-E389). This construct has been shown to display constitu-
tively kinase activity, even in the presence of inhibitors of upstream activators. Clones stably expressing this construct were selected by exposure to G418. Due to the 24 hour vs 72 hour
incubation lengths, the concentration of lapatinib (5-fold) and BEZ235 (7.5-fold) usedwas higher than in Fig. 1 accounting for the differential apoptotic responses. A–B. UMUC-6 parental
cells and UMUC-6-E389 were treated with either water or 2 μg/mL doxycycline for 48 h and then for 24 h with either DMSO control, 2.5 μM lapatinib, 750 nM BEZ235, or the drug
combination. The cells were stained with antibodies against the HA tag, cleaved caspase 3, and/or phosphorylated S6. In addition, the DNA in the cells was stained with DAPI. The cells
were then analyzed by ﬂow cytometry on a FACSCalibur. The levels of pS6 (A) and cleaved caspase 3 (B) in the HA positive population of the doxycycline-treated UMUC-6-E389 cells
were compared to the populations of doxycycline (-) UMUC-6-E389. C–D Quantiﬁcations of the ﬂow cytometry data. The bars represent the mean of either two (pS6) or four (Cl. Casp.
3) experiments. Error bars represent the standard error for each experiment. The * indicates a p-value b .05 and the ** indicates a p-value b .01.
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known, and p70S6K is often used as a “biomarker” in studies utilizing
drugs that inhibit these pathways, this is the ﬁrst demonstration that
p70S6K activity is sufﬁcient to rescue cells from apoptosis caused by
simultaneously inhibiting both pathways. Our data also support the
more general concept that targeting critical nodes can provide an alterna-
tive to drug combinations as a means for overcoming resistance to
targeted anti-cancer therapies that arise due to adaptive or compensatory
signaling
Resistance to targeted therapies often involves the activation of
compensatory signaling pathways, and it is increasingly appreciated
that there is a potential therapeutic beneﬁt from co-targeting an
oncogenic driver and an adaptive response. Because of the complexity
of molecular adaptations, it can be difﬁcult to determine which of the
numerous induced changes in kinome and transcriptome is likely to
be most appropriate for targeting. For example, Duncan et al. [12]
utilized phosphoproteomic techniques to describe extensive “kinome
rewiring” following treatment of triple negative breast cancer models
with MEK inhibitors. Gioeli et al. [1] showed profound alterations
following MEK inhibition of prostate cancer xenografts, not only in
protein phosphorylation but also in the transcriptome. For genetically
complex cancers such as head and neck, lung, bladder and melanoma,
it has not been possible to reliably utilize genomic alterations to identify
the most effective combinations [16]. Therefore, we developed a high-
throughput chemical genetic protocol for empirically identifying func-
tionally signiﬁcant compensatory signaling interactions. Using multiple
iterations of this methodology, we showed a compensatory interaction
between HER-family and PI3K signaling in both bladder and HNSCC
cell lines that manifested as synergistic growth inhibition upon co-
inhibition of these two signaling pathways.Mutational activation of the PI3K pathway, whether through loss of
PTEN expression or gain-of-function PIK3CA mutations, has been dem-
onstrated to act as amediator of resistance to anti-HER-family therapies
both in vitro and in vivo [17]. Two of the three cell lines that demonstrat-
ed sensitivity to this combination in our studies contain activating
PIK3CA mutations (SCC-61-E542K [27] and UMUC-6-E545K [14]. How-
ever, a third cell line that was sensitive to this inhibitor combination,
Cal27, does not contain PIK3CA mutations at any of the canonical loca-
tions for mutations in exons 1, 4, 5, 6, 7, 9, and 20 [27]. This cell line
also expresses full length, non-mutated PTEN [14,28]. Additionally, an-
other cell line containing an activating PIK3CA mutation, the bladder
cancer cell line 253-J, did not show sensitivity to the drug combination
[14]. Therefore, it does not appear thatmutational activation of the PI3K
signaling pathway at the level of PIK3CA or PTEN is sufﬁcient or
necessary for sensitivity to co-inhibition of HER-family and PI3K/
mTOR signaling. This underscores the point that analysis of genetic
alternationsmaynot be adequate for guiding the construction of combi-
nation therapies in all cases.
Since the mutational status of the PI3K signaling pathway does not
predict sensitivity to the combination, we sought to identify a biomark-
er that predicted response to HER family and PI3K/mTOR co-inhibition.
Utilizing RPPA technology, we discovered that phosphorylation of the
ribosomal protein S6 is strongly inhibited at multiple residues upon
combination drug treatment, and that none of the other protein phos-
phorylations exhibited a synergistic change in phosphorylation compa-
rable to the synergistic change in cytotoxicity. S6 phosphorylation has
been described as a marker for malignant progression in both bladder
[29] and squamous cell [30,31] cancers. In addition, decreases in S6
phosphorylation have been correlated with anti-tumor efﬁcacy of
targeted drugs in pre-clinical studies [32]. S6 phosphorylation is also
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Fig. 4. Direct targeting of p70S6K phenocopies the effects of combination treatment. A. UMUC-6, Cal27 and SCC61 cells were treated with increasing concentrations of AT7867 (ranging
from .39 to 25 μM for 72 h. Data points represent an average of three independent experiments. Error bars represent the standard error of the mean. B. Cal27 cells were treated with in-
creasing concentrations of AT7867 (ranging from .39 to 25 μM) for 1 h. Levels of phosphorylated and total S6, as well as tubulin as a loading control, were assessed byWestern blot. Images
are representative of three independent experiments. C. Cal27 cells were treatedwith increasing concentrations of AT7867 (ranging from .39 to 12.5 μM) for 72 h. Apoptosis was assessed
by ﬂow cytometry staining for cleaved caspase 3. D. Quantiﬁcation of the ﬂow cytometry data from C as well as for UMUC-6 and SCC-61. Each bar represents the average of three inde-
pendent experiments. Error bars represent the standard error of the mean. E. Cal27 cells were treated with either vehicle control or 2.5 μM Ro31-8220 for 72 h. Growth inhibition was
assessed by alamarBlue. Each bar represents the average of 3 independent experiments. Error bars represent the standard error of themean. F. Cal27 cells were treatedwith either vehicle
control or 2.5 μMRo31-8220 for 1 h. Western blotting was performed for the indicated S6 phosphorylations as well as total S6 protein. Tubulin was used as a loading control. Images are
representative of 3 independent experiments.
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and a pharmacodynamic marker of drug efﬁcacy [33].
Since S6 phosphorylation is a validated biomarker, we tested
whether the other responsive cell lines displayed a similar pattern
of S6 phosphorylation in response to HER-family and PI3K/mTOR
inhibitor treatment. S6 phosphorylation was signiﬁcantly decreased
by combination treatment in both Cal27 and SCC61 to a similar extent
as in UMUC-6. These data indicate that inhibition of S6 phosphorylation
does correlate to responsiveness to the HER-family and PI3K/mTOR
inhibitor combination. Interestingly, the changes in S6 phosphorylation
in response to treatment with these inhibitors utilized as single agents
varied between cell lines. In UMUC-6 and SCC61, the two cell lines
with activating PIK3CAmutations, treatment with a HER-family inhibi-
tor had only a modest effect on S6 phosphorylation. In contrast, HER-
family inhibition in Cal27 cells resulted in an over 50% decrease in S6
phosphorylation. Inhibition of PI3K/mTOR produced similarly variable
results. In UMUC-6 cells, treatment with LY249002 resulted in a robustdecrease in S6 phosphorylation, especially at Serine 235/236. In
contrast, both HNSCC cell lines displayed only modest inhibition of S6
phosphorylation upon PI3K/mTOR inhibition. These differences can
most likely be accounted for by differences in the upstream signaling
states of the three cell lines. This may indicate that the combination
of HER-family and PI3K/mTOR inhibition, combined with use of S6
phosphorylation as a biomarker, may be useful in a broad variety of
genetic backgrounds. Importantly, these ﬁndings also suggest that
p70S6K could be a therapeutic target in a wide variety of cancers
that differ in upstream mechanisms of activation of the MAP and
PI3K pathways.
It is generally acknowledged that p70S6K plays a role in regulating
important cellular functions. However, the exact nature of that role is
the subject of some dispute. It was initially believed that the main
function of p70S6K was to regulate the translation of 5′ terminal
oligopyrimidine tract (5’TOP) mRNAs through phosphorylation of S6.
Ruvinsky et al. [34] showed that mutation of the serine sites of
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nine residues did not have an effect on 5′TOP mRNA translation in
mouse embryonic ﬁbroblasts. Therefore, the importance of p70S6K
signaling may lie in translation-independent cell functions such as reg-
ulation of proliferation [35], neurological function [36], andmetabolism
[37]. Our RPPA and Western blot data showed that a synergistic
decrease in S6 phosphorylation correlated with synergistic apoptosis,
a biological process regulated by p70S6K activity [38]. These data
cannot, however, tell us whether p70S6K serves as a regulatory node
by integrating signals fromHER-family and PI3K/mTOR signaling to reg-
ulate this biology. Therefore, we tested the role of p70S6K using both
pharmacological and genetic techniques. The data generated by both
approaches, particularly by use of the constitutively active E389-
p70S6K construct to protect UMUC-6 cells from apoptosis, demonstrate
that p70S6K does in fact play a critical role in mediating the synergy
caused by co-inhibition of upstream signaling. Use of direct inhibitors
of p70S6K enzymatic activity to recapitulate the biological effects of in-
hibition of HER-family and p70S6K signaling demonstrates the
druggability of this node, making it an attractive target for therapeutic
intervention.
A study by She et al. [39] demonstrated that knockdown of eu-
karyotic initiation factor 4E binding protein (4E-BP1), but not
p70S6K, recapitulated the growth inhibitory effects of co-inhibition
of AKT and MEK in breast cancer cell lines harboring both activating
PIK3CA and Ras mutations. When phosphorylated, 4E-BP1 binds to
and inactivates eukaryotic initiation factor 4E (eIF4E), which plays
an important role in mediating cell growth and proliferation through
regulation of 5′-cap dependent mRNA translation [40]. Thus, the She
study identiﬁed 4E-BP1 as a critical node of convergence between
Ras and AKT signaling. However, we did not detect a signiﬁcant de-
crease of 4E-BP1phosphorylation upon combination treatment
with HER-family and PI3K/mTOR inhibitors. Also in contrast to that
study, our RPPA and epistasis data indicate that p70S6K, not 4E-
BP1, is the critical node of convergence between the two pathways
that were inhibited in this study. It is possible that the differences
observed between the two studies are due to the dissimilar genetic
backgrounds of the cell lines used. The She study focused on cell
lines in which activating mutations of both the Ras/MEK/ERK and
PI3K/AKT pathways coexisted. Conversely, none of the cell lines in
our current study contain mutations activating the Ras/MEK/ERK
pathway.
De novo and acquired resistancemediated through up-regulation of
PI3K pathway signaling has been reported in patients treatedwith HER-
family inhibitors such as lapatinib [41] thus leading to attempts to uti-
lize combinations of inhibitors of Her-family tyrosine kinases and
PI3K/mTOR. By identifying p70S6K as a node between these signaling
pathways, we have identiﬁed a potential target that can overcome this
resistance using a single drug.5. Conclusions
Combinations of targeted cancer therapies are viewed as necessary
to block adaptive resistance mechanisms. However, signiﬁcant issues
including enhanced toxicities and the potential requirement of drug
company cooperation are impediments to the implementation of com-
bination drug therapy. Identiﬁcation of critical nodes in cell signaling
networks is an attractive alternative to inhibiting multiple targets.
Using phosphoproteomic, empirical and epistasis experiments we
show that p70S6K is a critical node integrating PI3K and HER family
signaling. Moreover, direct inhibition of p70S6 kinase phenocopies co-
inhibition of HER family and PI3 kinase. These data indicate that direct
targeting of critical nodes may be a viable strategy to overcome the
limitations of combinatorial drug therapies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cellsig.2014.03.013.Authors' Contributions
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